Healthcare
Live Price
Offline$17.53
+3.36% today
1Y Change
-19.93%
Window
Jun 23, 2025 → Jun 10, 2026
Coverage: 243 bars · Jun 23, 2025 → Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sarepta Therapeutics, Inc. (SRPT) is a Healthcare stock with a market cap of $2.26B and listed on NASDAQ. The stock last traded around $17.53 and down 19.9% across the available one-year price window (Jun 23, 2025 → Jun 10, 2026). Baseline metrics include revenue growth of +15.6%, EPS growth of -388.7%, a dividend yield of 0.0%. What stands out right now is revenue +15.6%, EPS -388.7%, free cash flow +12.8% with operating margin -31.8% and ROIC -30.9%. Valuation is more restrained than many high-expectation growth names at price/sales 1.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SRPT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SRPT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SRPT Max Drawdown
-45.70%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SRPT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$701.9M
-24.8% YoY
FY Net Income
-$418.8M
+40.5% YoY
Free Cash Flow
-$481.7M
-34.7% YoY
Revenue Growth
+15.6%
EPS Growth
-388.7%
Gross Margin
61.8%
Net Margin
-32.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.2B | 1.9B | 1.2B | 933M | 702M |
| Gross Profit | 1.3B | 1.6B | 1.1B | 793M | 605M |
| Operating Income | -658M | 218M | -268M | -536M | -460M |
| EBITDA | -648M | 317M | -454M | -595M | -317M |
| Net Income | -713M | 235M | -536M | -703M | -419M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 801M | 1.1B | 428M | 967M | 2.1B |
| Total Assets | 3.3B | 4.0B | 3.3B | 3.1B | 3.1B |
| Total Liabilities | 2.2B | 2.4B | 2.4B | 2.7B | 2.2B |
| Shareholder Equity | 1.1B | 1.5B | 859M | 385M | 928M |
| Total Debt | 1.0B | 1.3B | 1.4B | 1.6B | 1.2B |
| Net Debt | 238M | 240M | 968M | 651M | -962M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
443M
-36.2% YoY
Capital Expenditures
38M
-19.3% YoY
Free Cash Flow
482M
-34.7% YoY
Key ratios
Gross Margin
61.8%
Operating Margin
-31.8%
Net Margin
-32.5%
ROE
-57.5%
Debt / Equity
0.91x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.